The PCCTC at ASCO GU 2025
Science from seven Prostate Cancer Clinical Trials Consortium (PCCTC) studies will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, CA on February 13-15. ASCO GU features the latest high-impact science, multidisciplinary expertise, and evidence-based practices in GU cancer care. PCCTC investigators will share results from their innovative, hypothesis driven, multicenter studies, as well as summaries of trials in progress which will help shape the prostate cancer therapeutic landscape.
Abida W, Chen Y, McHugh D, Morris M, Wu F, Peng P, Hennessy K, Wang H, Fan J, Zaidi S. A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 43, 2025 (suppl 5; abstr TPS290)
Arham AB, Thomas C, Castaneda I, Ruder S, Zakharia Y, Appleman L, Osborne J, Philips G, Nordquist L, D'souza A, Wulff-Burchfield E, Posadas E, Agarwal N, Christos P, Adra N, Nanus D, Tagawa S. Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC). J Clin Oncol 43, 2025 (suppl 5; abstr 172)
Atiq M, Stadler W, Page A, Catenacci M, Patnaik A, Paner G, Eggener S, Szmulewitz R. Neoadjuvant androgen deprivation therapy with enzalutamide plus the glucocorticoid receptor modulator relacorilant versus placebo for patients with high-risk localized prostate cancer. J Clin Oncol 43, 2025 (suppl 5; abstr TPS436)
Kyriakopoulos C, Chen YH, Jeraj R, Duan F, Tripathi A, Kosoff D, Garje R, Pachynski R, Parikh R, Harzstark A, Adra N, Maughan B, Zakharia Y, Corn P, Liu G, Carducci M, Luo J, Antonarakis E. CTC and AR-V7 analysis in the ECOG-ACRIN 8153 (CHAARTED2) randomized trial: Abiraterone (Abi) with or without cabazitaxel (Abi-Cabazi) in extensive mCRPC following docetaxel. J Clin Oncol 43, 2025 (suppl 5; abstr 181)
McManus H, Howard L, Crowell KA, Hyslop Y, Autio K, Rathkopf D, Dreicer R, Chi K, Ong M, Mateo J, Deborah D, Esteban E, Khoo V, McMannis A, Green R, Pileggi S, Vinson J, Kantoff P, Mucci M, George D. Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer. J Clin Oncol 43, 2025 (suppl 5; abstr 65)
Morris M, Kiess A, Nordquist L, Gupta S, George D, Messmann R, Kantoff P, Nauseef J, Bander N, Antonarakis E. CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer. J Clin Oncol 43, 2025 (suppl 5; abstr TPS289)
Reichert Z, Hussain M, Lovett J, Kocherginsky M, Paller C, Agarwal N, Adra N, Zhang J, Picus J, Szmulewitz R, Kuzel T, Tagawa S, Bazzi L, Whang Y, Stephenson R, Dreicer R, Daniel Shevrin D, Rettig M, Antonarakis E, Morgan T. Circulating tumor cell expression analysis from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway). J Clin Oncol 43, 2025 (suppl 5; abstr 199)
